Pro Medicus and CSL show divergent returns in ASX healthcare sector

Pro Medicus Ltd and CSL Ltd have shown divergent performance among major healthcare stocks on the ASX 200. An analysis of a $10,000 investment made three years ago reveals that while CSL shares have faced selling pressure, the total value of that investment—including approximately $12.55 per share in dividends—would be worth roughly $7,474 today.

Pro Medicus, a provider of radiology IT software including its flagship Visage software, has historically seen different returns. The company specializes in Radiology Information Systems (RIS) and Picture Archiving and Communication Systems (PACS), allowing radiologists to view large medical images remotely on mobile devices. Despite the sector's potential for sticky revenue and growth in global healthcare spending, Pro Medicus shares have seen a decline of 27.7% since the start of 2025.